177Lu-DOTATATE for advanced breast cancer with targeted receptors
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, and your estimated life expectancy is over 6 months
- You have confirmed breast cancer that is stage IV or has come back with spread to other organs
- Your cancer has progressed after at least two standard treatment lines and/or one chemotherapy line (endocrine-only is not enough)
- A special scan shows enough tumor receptors (SSTR) for this drug—more than 50% of lesions must take up DOTATATE
- You can have a biopsy before starting treatment, and you’re well enough to do daily activities (ECOG 0–2)
- Your recent blood tests and organ function are adequate (blood counts, liver tests, kidney function, and no recent major blood transfusions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This Phase 2 trial tests a targeted radioactive medicine called 177Lutetium-DOTATATE in children with high-risk neuroblastoma that has returned or did not respond to treatment. It’s designed for tumors that show strong uptake on special scans, which may help the medicine find and treat cancer cells.
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.